Overview of the safety of newer antiepileptic drugs.Epilepsia. 1997; 38 Suppl 1:S45-51.E
Abstract
Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management. The safety and interaction profiles of the newer AEDs have also been intensively studied. Safety data are available for six of the newer AEDs, lamotrigine (LTG), vigabatrin (VGB), gabapentin (GBP), tiagabine (TGB), felbamate (FBM), and topiramate (TPM). The potential for the most recently developed AEDs for producing rare idiosyncratic reactions cannot be ascertained until additional patient exposures have been reported from careful postmarketing surveillance.
Links
MeSH
Pub Type(s)
Journal Article
Review
Language
eng
PubMed ID
9092960
Citation
Shorvon, S, and H Stefan. "Overview of the Safety of Newer Antiepileptic Drugs." Epilepsia, vol. 38 Suppl 1, 1997, pp. S45-51.
Shorvon S, Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia. 1997;38 Suppl 1:S45-51.
Shorvon, S., & Stefan, H. (1997). Overview of the safety of newer antiepileptic drugs. Epilepsia, 38 Suppl 1, S45-51.
Shorvon S, Stefan H. Overview of the Safety of Newer Antiepileptic Drugs. Epilepsia. 1997;38 Suppl 1:S45-51. PubMed PMID: 9092960.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Overview of the safety of newer antiepileptic drugs.
AU - Shorvon,S,
AU - Stefan,H,
PY - 1997/1/1/pubmed
PY - 1997/1/1/medline
PY - 1997/1/1/entrez
SP - S45
EP - 51
JF - Epilepsia
JO - Epilepsia
VL - 38 Suppl 1
N2 - Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management. The safety and interaction profiles of the newer AEDs have also been intensively studied. Safety data are available for six of the newer AEDs, lamotrigine (LTG), vigabatrin (VGB), gabapentin (GBP), tiagabine (TGB), felbamate (FBM), and topiramate (TPM). The potential for the most recently developed AEDs for producing rare idiosyncratic reactions cannot be ascertained until additional patient exposures have been reported from careful postmarketing surveillance.
SN - 0013-9580
UR - https://www.unboundmedicine.com/medline/citation/9092960/Overview_of_the_safety_of_newer_antiepileptic_drugs_
L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0013-9580&date=1997&volume=38&issue=&spage=S45
DB - PRIME
DP - Unbound Medicine
ER -